vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Empire State Realty OP, L.P. (ESBA). Click either name above to swap in a different company.

Empire State Realty OP, L.P. is the larger business by last-quarter revenue ($199.2M vs $196.0M, roughly 1.0× Axsome Therapeutics, Inc.). Empire State Realty OP, L.P. runs the higher net margin — 16.1% vs -14.6%, a 30.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 0.8%). Empire State Realty OP, L.P. produced more free cash flow last quarter ($50.6M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 4.9%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Empire State Realty OP, L.P. is a real estate operating partnership focused on owning, managing, and leasing premium commercial and retail properties primarily in the New York City metropolitan area. Its portfolio includes iconic landmarks like the Empire State Building, serving corporate tenants, retail brands and tourism-related business segments.

AXSM vs ESBA — Head-to-Head

Bigger by revenue
ESBA
ESBA
1.0× larger
ESBA
$199.2M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+64.2% gap
AXSM
65.0%
0.8%
ESBA
Higher net margin
ESBA
ESBA
30.7% more per $
ESBA
16.1%
-14.6%
AXSM
More free cash flow
ESBA
ESBA
$69.3M more FCF
ESBA
$50.6M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
4.9%
ESBA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
ESBA
ESBA
Revenue
$196.0M
$199.2M
Net Profit
$-28.6M
$32.2M
Gross Margin
Operating Margin
-13.8%
17.8%
Net Margin
-14.6%
16.1%
Revenue YoY
65.0%
0.8%
Net Profit YoY
61.9%
71.2%
EPS (diluted)
$-0.55
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
ESBA
ESBA
Q4 25
$196.0M
$199.2M
Q3 25
$171.0M
$197.7M
Q2 25
$150.0M
$191.3M
Q1 25
$121.5M
$180.1M
Q4 24
$118.8M
$197.6M
Q3 24
$104.8M
$199.6M
Q2 24
$87.2M
$189.5M
Q1 24
$75.0M
$181.2M
Net Profit
AXSM
AXSM
ESBA
ESBA
Q4 25
$-28.6M
$32.2M
Q3 25
$-47.2M
$13.6M
Q2 25
$-48.0M
$11.4M
Q1 25
$-59.4M
$15.8M
Q4 24
$-74.9M
$18.8M
Q3 24
$-64.6M
$22.8M
Q2 24
$-79.3M
$28.6M
Q1 24
$-68.4M
$10.2M
Operating Margin
AXSM
AXSM
ESBA
ESBA
Q4 25
-13.8%
17.8%
Q3 25
-27.0%
19.9%
Q2 25
-24.5%
18.4%
Q1 25
-46.9%
14.3%
Q4 24
-61.1%
21.7%
Q3 24
-59.8%
22.7%
Q2 24
-89.5%
20.8%
Q1 24
-89.7%
17.1%
Net Margin
AXSM
AXSM
ESBA
ESBA
Q4 25
-14.6%
16.1%
Q3 25
-27.6%
6.9%
Q2 25
-32.0%
6.0%
Q1 25
-48.9%
8.8%
Q4 24
-63.1%
9.5%
Q3 24
-61.7%
11.4%
Q2 24
-91.0%
15.1%
Q1 24
-91.1%
5.6%
EPS (diluted)
AXSM
AXSM
ESBA
ESBA
Q4 25
$-0.55
$0.11
Q3 25
$-0.94
$0.05
Q2 25
$-0.97
$0.04
Q1 25
$-1.22
$0.05
Q4 24
$-1.54
$0.07
Q3 24
$-1.34
$0.08
Q2 24
$-1.67
$0.10
Q1 24
$-1.44
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
ESBA
ESBA
Cash + ST InvestmentsLiquidity on hand
$322.9M
$132.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
Total Assets
$689.8M
$4.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
ESBA
ESBA
Q4 25
$322.9M
$132.7M
Q3 25
$325.3M
$154.1M
Q2 25
$303.0M
$94.6M
Q1 25
$300.9M
$187.8M
Q4 24
$315.4M
$385.5M
Q3 24
$327.3M
$421.9M
Q2 24
$315.7M
$535.5M
Q1 24
$331.4M
$333.6M
Stockholders' Equity
AXSM
AXSM
ESBA
ESBA
Q4 25
$88.3M
Q3 25
$73.7M
Q2 25
$73.1M
Q1 25
$53.2M
Q4 24
$57.0M
Q3 24
$92.9M
Q2 24
$102.9M
Q1 24
$144.0M
Total Assets
AXSM
AXSM
ESBA
ESBA
Q4 25
$689.8M
$4.5B
Q3 25
$669.3M
$4.1B
Q2 25
$639.8M
$4.1B
Q1 25
$596.7M
$4.1B
Q4 24
$568.5M
$4.5B
Q3 24
$561.5M
$4.4B
Q2 24
$548.2M
$4.4B
Q1 24
$545.7M
$4.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
ESBA
ESBA
Operating Cash FlowLast quarter
$-18.7M
$249.1M
Free Cash FlowOCF − Capex
$-18.7M
$50.6M
FCF MarginFCF / Revenue
-9.6%
25.4%
Capex IntensityCapex / Revenue
0.0%
99.6%
Cash ConversionOCF / Net Profit
7.74×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$109.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
ESBA
ESBA
Q4 25
$-18.7M
$249.1M
Q3 25
$1.0M
$105.3M
Q2 25
$-32.4M
$26.7M
Q1 25
$-43.4M
$83.1M
Q4 24
$-26.2M
$260.9M
Q3 24
$-18.6M
$102.8M
Q2 24
$-30.1M
$37.1M
Q1 24
$-53.5M
$70.9M
Free Cash Flow
AXSM
AXSM
ESBA
ESBA
Q4 25
$-18.7M
$50.6M
Q3 25
$988.0K
$72.8M
Q2 25
$-32.4M
$-55.1M
Q1 25
$-43.7M
$41.1M
Q4 24
$-26.2M
$88.0M
Q3 24
$-18.7M
$-65.1M
Q2 24
$-30.2M
$19.5M
Q1 24
$-53.6M
$23.2M
FCF Margin
AXSM
AXSM
ESBA
ESBA
Q4 25
-9.6%
25.4%
Q3 25
0.6%
36.8%
Q2 25
-21.6%
-28.8%
Q1 25
-36.0%
22.8%
Q4 24
-22.1%
44.5%
Q3 24
-17.9%
-32.6%
Q2 24
-34.6%
10.3%
Q1 24
-71.4%
12.8%
Capex Intensity
AXSM
AXSM
ESBA
ESBA
Q4 25
0.0%
99.6%
Q3 25
0.0%
16.5%
Q2 25
0.0%
42.8%
Q1 25
0.3%
23.4%
Q4 24
0.0%
87.5%
Q3 24
0.1%
84.1%
Q2 24
0.1%
9.3%
Q1 24
0.1%
26.3%
Cash Conversion
AXSM
AXSM
ESBA
ESBA
Q4 25
7.74×
Q3 25
7.72×
Q2 25
2.35×
Q1 25
5.27×
Q4 24
13.88×
Q3 24
4.51×
Q2 24
1.30×
Q1 24
6.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

ESBA
ESBA

Real Estate Segment$163.8M82%
Observatory Segment$35.2M18%

Related Comparisons